IONS vs ITCI Stock Comparison
Compare IONS and ITCI across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between IONS and ITCI?
ITCI leads the current stock comparison as Intra-Cellular Therapies, Inc., with the clearest separation coming from risk resilience and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Ionis Pharmaceuticals, Inc. vs Intra-Cellular Therapies, Inc.
ITCI leads
ITCI leads by 21 AIQ points, primarily on Risk Resilience and Quality, and the lead has widened from 16 points over 30 sessions. Wall Street currently favors IONS on target upside.
Stable: 3 of 5 evidence groups support ITCI, and its lead is widening.
Ionis Pharmaceuticals, Inc.
Intra-Cellular Therapies, Inc.
The Algovestiq AIQ Score currently favors ITCI over IONS, 54 versus 33 as of Sep 11, 2026. ITCI's advantage is driven primarily by stronger risk resilience and quality. Analyst target upside, however, currently favors IONS. 3 of 5 covered evidence groups favor ITCI today, and the comparison is rated Stable on stability. ITCI lead: Strengthening — the AIQ differential moved from 16 to 21 points over 30 sessions.
Compare Ionis Pharmaceuticals, Inc. and Intra-Cellular Therapies, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare IONS and ITCI against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Risk Resilience41 vs 82ITCI +41
- Quality30 vs 60ITCI +30
- Value34 vs 34Even
3 of 5 evidence groups favor ITCI. ITCI’s edge is concentrated in risk resilience and quality.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
Largest factor move: Momentum +3
No new signals fired.
No factor moved materially.
No new signals fired.
ITCI's lead was unchanged in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — IONS and ITCI both carry a full feed there.
The central trade-off
ITCI (Intra-Cellular Therapies, Inc.): the stronger current systematic profile, led by risk resilience and quality.
IONS (Ionis Pharmaceuticals, Inc.): the counter-case, on analyst expectations.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
ITCIITCI on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
ITCIITCI on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
EvenThe two are level on Momentum.
Lower downside
ITCIITCI on Risk Resilience, by 41 points.
Analyst upside
IONSIONS on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors ITCI, analyst targets favor IONS. That disagreement is the most useful thing on this page.
| Measure | IONS | ITCI | Note |
|---|---|---|---|
| Implied upside to target | +82.2% | +0.1% | IONS has more room |
| Target dispersion | +69.8% | 0% | Lower is tighter analyst agreement |
| Consensus | Buy | Hold | Context, not a primary driver |
| Analysts covering | 12 | 1 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 5 covered evidence groups favor ITCI. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | ITCI | 33 vs 54 |
| Fundamentals | ITCIon balance | revenue growth 8.9% vs 13.7%; EPS growth -23.2% vs 3.2%; TTM ROE -110.8% vs -8.6%; gross margin 98.2% vs 91.6%; operating margin -68.1% vs -17.1% — ITCI takes 4 of 5 decided legs, not all of them |
| Valuation | Even | Value 34 vs 34 |
| Technicals | Not covered | Not covered |
| Risk Resilience | ITCI | Risk Resilience 41 vs 82 |
| Analyst expectations | IONS | Target upside 82.2% vs 0.1% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of IONS and ITCI and are excluded from the count.
AIQ Decision Stability
The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.
- The AIQ gap is wide at 21 points. (supports the conclusion holding)
- The leader's advantage has been widening. (supports the conclusion holding)
- The lead has been steady session to session. (supports the conclusion holding)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on ITCI.
How the comparison changed
119 daily snapshots · May 4 – Sep 10ITCI lead: Strengthening — the AIQ differential moved from 16 to 21 points over 30 sessions.
- Today
- ITCI +21
- 33 vs 54
- 7 sessions ago
- ITCI +18
- 36 vs 54
- 30 sessions ago
- ITCI +16
- 41 vs 57
- 90 sessions ago
- ITCI +10
- 47 vs 57
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
0 bullish / 3 bearish / 1 neutral
- Death Cross Active — bearish, trend, long horizon (22.37%)
- Downtrend Structure Active — bearish, trend, long horizon
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (3.87%)
No active signals
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -2.59%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1IONS closes the Risk Resilience gap — currently 41 points behind, the largest single contributor to ITCI's edge.
- 2IONS's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3ITCI starts generating bearish momentum or trend signals.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
ITCI leads on balance| Metric | IONS | ITCI |
|---|---|---|
| Revenue growth (YoY) | 8.9% | 13.7% |
| EPS growth (YoY) | -23.2% | 3.2% |
| Gross margin | 98.2% | 91.6% |
| Operating margin | -68.1% | -17.1% |
| Return on equity (TTM) | -110.8% | -8.6% |
| Debt to equity | 5.5 | 0.01 |
Performance
Split across windows| Metric | IONS | ITCI |
|---|---|---|
| 1 week (5 sessions) | -9.3% | — |
| 1 month (20 sessions) | -1.6% | — |
| 3 months (63 sessions) | -24.1% | — |
| 6 months (126 sessions) | -25.6% | — |
| Year to date | -29.7% | — |
| 1 year (252 sessions) | -8.6% | — |
Technicals
Split| Metric | IONS | ITCI |
|---|---|---|
| RSI (14) | 40.1 | — |
| ADX (14) | 21.2 | — |
| Price vs 50-day | -9.3% | — |
| Price vs 200-day | -23.9% | — |
| Volatility (1M, annualized) | 37.3% | — |
Risk
ITCI is the more resilient| Metric | IONS | ITCI |
|---|---|---|
| Beta | 0.37 | — |
| Sharpe ratio | -0.25 | — |
| Sortino ratio | -0.26 | — |
| Max drawdown | -40.1% | — |
| Current drawdown | -35.7% | — |
| Annualized volatility | 39.9% | — |
| Value at risk (95%) | -3.2% | — |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, IONS or ITCI?
On the Algovestiq AIQ Score, ITCI is the stronger of the two as of Sep 11, 2026, scoring 54 against IONS's 33. The edge comes from risk resilience and quality. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is IONS or ITCI the better buy right now?
ITCI carries the stronger systematic profile as of Sep 11, 2026, and the comparison is rated Stable — 3 of 5 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.
Why does the AIQ Score favor ITCI over IONS?
The composite weights Quality, Value, Momentum and Risk Resilience. ITCI leads Risk Resilience by 41 points; ITCI leads Quality by 30 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, IONS or ITCI?
Analyst price targets imply +82.2% upside for IONS and +0.1% for ITCI, so the Street currently favors IONS. That points the opposite way to the AIQ Score, which favors ITCI. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, IONS or ITCI?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, IONS or ITCI?
ITCI on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, IONS or ITCI?
The two are level on Momentum. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, IONS or ITCI?
ITCI is the more resilient of the two, so the other name carries the higher downside risk. ITCI on Risk Resilience, by 41 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is IONS more profitable than ITCI?
The profitability evidence is mixed: gross margin 98.2% vs 91.6%; operating margin -68.1% vs -17.1%; ttm roe -110.8% vs -8.6%. IONS leads on one measure and ITCI on two measures, and there is no single profitability composite that resolves the split — which of the two reads as "more profitable" depends on whether you weight pricing power or operating leverage.
Is ITCI's lead over IONS getting stronger or weaker?
ITCI lead: Strengthening — the AIQ differential moved from 16 to 21 points over 30 sessions. This is measured from 119 daily comparison snapshots between 2026-05-04 and 2026-09-10. The lead has not changed hands in that window.
What would change the IONS vs ITCI verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: IONS closes the Risk Resilience gap — currently 41 points behind, the largest single contributor to ITCI's edge; IONS's Death Cross Active resolves — a bearish trend rule currently active against it; ITCI starts generating bearish momentum or trend signals; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about IONS and ITCI?
IONS: 0 bullish / 3 bearish / 1 neutral. ITCI: No active signals. The most decision-relevant rule on IONS is Death Cross Active (bearish, long horizon).
Compare IONS and ITCI with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.